Sector News

Shire tops US reputation survey

June 19, 2015
Life sciences
Shire has been named the most reputable pharma company in the US in a new report from the Reputation Institute
 
The report used over 50,000 consumer rankings to measure the public’s perception of pharma firms based on seven dimensions: innovation, leadership, governance, citizenship, workplace, performance, and products and services. This was then translated into a ‘RepTrack’ score.
 
Shire came out on top­ with a score of 77.55. Sanofi, Bayer and Boerhinger Ingelheim were close behind with scores of 76, 75, and 74 respectively. The top five was rounded off by generics firm Perrigo, while AbbVie, Roche, Lilly, Novartis and Takeda filled out the top 10.
 
They key drivers behind a firm’s reputation score were whether it offers high quality products, whether it is an ethical and transparent company, and whether it is a good corporate citizen.
 
The survey also found that 60% of people’s decision to buy, recommend or invest in a company depends on its reputation, and that 54% of consumers would give reputable companies the benefit of a doubt in a crisis compared with only 20% for companies with a poor reputation.
 
A UK PatientView survey released this month also placed Sanofi highly for reputation among patients, with the French firm ranking first for its pricing strategies and innovative products.
 
But there were noticeable differences in the other results between the two surveys – for example, the rest of PatientView’s top five consisted of Pfizer, Roche, GSK and Novartis.
 
By George Underwood
 
 

comments closed

Related News

October 2, 2022

GSK names Julie Brown, a 25-year AstraZeneca veteran, its first woman CFO

Life sciences

Five years ago, GSK made headlines when it hired Emma Walmsley to become the first woman to run a major pharmaceutical company. Now the Big Pharma has brought in another woman to control the company’s finances. Julie Brown will be GSK’s next chief financial officer. Brown, currently the chief operating and financial officer at fashion and beauty brand Burberry Group, is set to replace Iain Mackay.

October 2, 2022

Moderna creates new launch preparation role, poaches Novartis exec as manufacturing lead

Life sciences

Moderna created a new role responsible for “building out the company’s organization to support its growing pipeline.” Starting first thing 2023, Juan Andres, Moderna’s manufacturing head, will step into this new role under the title president of strategic partnerships and enterprise expansion, the company said Thursday.

October 2, 2022

Torrent Pharma to acquire Curatio for $245.16m

Life sciences

The latest takeover is anticipated to boost the presence of Torrent in the dermatology segment. Indian company Torrent Pharmaceuticals has signed a definitive agreement for the complete acquisition of Curatio Healthcare for $245.16m (Rs20bn).